GlaxoSmithKline (GSK) has formed a partnership with ChemoCentryx
worth $1.5bn (€1.2bn) which will provide the company with access to
selected targets from one of the broadest pipelines of
chemokine-based therapeutics in the biotech...
Evotec and CHDI have formed a strategic partnership, which aims to
research and develop treatments for Huntington Disease (HD), a
genetic disorder that causes programmed degeneration of brain cells
and loss of intellectual faculties.
Charles River Laboratories becomes the ninth contract research
organisation (CRO) to open up a new pathology facility within the
Chicago Technology Park (CTP), reinforcing the emerging outsourcing
trend in pharmaceutical discovery...
Global drug development spending will top $105bn (€81.5bn) by 2010
and 40 per cent of this business is expected to be dished out in
outsourcing contracts - with contract research organisations (CROs)
Covance, the world's largest provider of drug-development services,
is bracing itself for the onslaught of protests by animal rights
activists who are demonstrating against the building of a $100m
(€78.6) laboratory in the US.
A new service introduced on the back of customer demand has been
launched by Aviva Systems Biology which make available a method for
genome-wide detection of promoters and enhancers that interact with
proteins or carry modifications.
Despite looming threats from cheap Asian competitors, European
contract research organisations (CROs) still have a fighting chance
in the global R&D outsourcing market, according to a report by
research analysts Frost & Sullivan.
Wyeth has announced that it has selected NovaScreen to conduct a
high-throughput screening (HTS) campaign, which makes use of
Caliper's microfluidic screening platform, which utilises
reproducible electrophoretic separation of...
Using human tissue to test new drugs at earlier stages of
development can speed drugs to market faster, however, human tissue
remains a scarce resource for drug firms - something that US firm
Asterand has set out to change.
As clinical trial activity in the Asia Pacific region continues to
boom, Novotech, the largest Australian owned contract research
organisation (CRO) has presented a checklist to help pharma firms
minimise risk when choosing a partner.